SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 424.83 |
| Enterprise Value ($M) | 190.44 |
| Book Value ($M) | 196.20 |
| Book Value / Share | 2.88 |
| Price / Book | 2.17 |
| NCAV ($M) | 190.75 |
| NCAV / Share | 2.80 |
| Price / NCAV | 2.23 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.31 |
| Return on Assets (ROA) | -0.56 |
| Return on Equity (ROE) | -0.62 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.72 |
| Current Ratio | 4.72 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 245.26 |
| Assets | 250.71 |
| Liabilities | 54.51 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 4.53 | 0.00 | |
| 13G | Perceptive Advisors Llc | 6.50 | 138.55 | |
| 13G | TCG Crossover GP II, LLC | 6.80 | ||
| 13G/A | BlackRock Inc. | 3.90 | -33.30 | |
| 13G | Panacea Innovation Ltd | 6.20 | ||
| 13G/A | Point72 Asset Management, L.P. | 4.70 | -7.73 | |
| 13G/A | Viking Global Investors Lp | 4.40 | -36.08 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 128,696 | 2,623,959 | 4.90 | |
| 95,596 | 1,305,657 | 7.32 | |
| 189,411 | 1,833,393 | 10.33 | |
| 283,077 | 1,902,341 | 14.88 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ALNY – Alnylam Pharmaceuticals, Inc. | ALXO – ALX Oncology Holdings Inc. |
| AMGN – Amgen Inc. | AMPH – Amphastar Pharmaceuticals, Inc. |
| AMRX – Amneal Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io